flufenamic acid has been researched along with Chronic Lung Injury in 1 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Major, T | 1 |
| Ball, AL | 1 |
| Stone, JP | 1 |
| Edge, RJ | 1 |
| Lopez-Castejon, G | 1 |
| Sjöberg, T | 1 |
| Andreasson, A | 1 |
| Brough, D | 1 |
| Steen, S | 1 |
| Fisher, AJ | 1 |
| Fildes, JE | 1 |
1 other study available for flufenamic acid and Chronic Lung Injury
| Article | Year |
|---|---|
Pro-IL-1β Is an Early Prognostic Indicator of Severe Donor Lung Injury During Ex Vivo Lung Perfusion.
Topics: Adult; Animals; Anti-Inflammatory Agents; Caspase 1; Female; Flufenamic Acid; Humans; Inflammasomes; | 2021 |